NASDAQ: AVBPArrivent Biopharma Inc Stock
$34.67+0.17 (+0.49%)
Updated Jul 2, 2026
AVBP Price
$34.67
Fair Value Price
$1.18
Market Cap
$1.61B
52 Week Low
$16.10
52 Week High
$35.83
P/E
-9.99x
P/B
4.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$145.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$134M
Beta
0.93
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AVBP Overview
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVBP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AVBP
Ranked#326 of 463
Ranked#326 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important AVBP news, forecast changes, insider trades & much more!
AVBP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVBP ($34.67) is overvalued by 2,829.09% relative to our estimate of its Fair Value price of $1.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVBP ($34.67) is not significantly undervalued (2,829.09%) relative to our estimate of its Fair Value price of $1.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVBP due diligence checks available for Premium users.
Valuation
AVBP fair value
Fair Value of AVBP stock based on Discounted Cash Flow (DCF)
Price
$34.67
Fair Value
$1.18
Overvalued by
2,829.09%
AVBP ($34.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVBP ($34.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.99x
Industry
17.59x
Market
8.54x
AVBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.98x
Industry
5.6x
AVBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$43.3M
Profit Margin
0%
AVBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$349.3M
Liabilities
$25.3M
Debt to equity
0.08
AVBP's short-term assets ($348.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVBP's short-term assets ($348.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.9M
Investing
$3.6M
Financing
$54.9M
AVBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVBP vs Biotech Stocks
Arrivent Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.